| 淡江大學 |
2004-01 |
Lemma Approach in a Time scales
|
錢傳仁; Chyan, Chuan-jen |
| 國立中山大學 |
2004 |
Lemnalia cervicorni, Dendronephthya gigantea及 Nephthea armata三種軟珊瑚活性成分之研究(I)
|
杜昌益; Chang-Yih Duh |
| 國立中山大學 |
2006 |
Lemnalia cervicorni、Dendronephthya gigantea 及Nephthea armata三種軟珊瑚活性成分之研究(III)
|
杜昌益 |
| 國立中山大學 |
2009-03-22 |
Lemnalol, a natural marine compound obtained from the Formosan soft coral Lemnalia cervicorni attenuates nociceptive responses and activity of the spinal glial cells in neuropathic rats
|
Y.C. Lin;S.Y. Huang;C.Y. Duh;Y.H. Jean;W.F. Chen;Z.H. Wen |
| 國立臺灣海洋大學 |
2012-01-01 |
Lemon ascorbate peroxidase: cDNA cloning and biochemical characterization
|
Ya-Han Dai;Chich-Yu Huang;Lisa Wen;Dey-Chyi Sheu;Chi-Tsai Lin |
| 國立臺灣海洋大學 |
2013 |
Lemon protein disulfide isomerase: cDNA cloning and biochemical characterization
|
Yu-Ting Chen;Lisa Wen;Kuo-Chuan Ho;Rong-Huay Juang;Chi-Tsai Lin |
| 臺大學術典藏 |
2020-01-06T03:09:14Z |
Lemon protein disulfide isomerase: cDNA cloning and biochemical characterization
|
Chen, Y.-T.; Wen, L.; Ho, K.-C.; Juang, R.-H.; Lin, C.-T.; KUO-CHUAN HO |
| 朝陽科技大學 |
2006 |
Lempel-Ziv資料壓縮方法之抗錯研究
|
曾顯文 |
| 中國醫藥大學 |
2014-07-17 |
LEM避免UVA誘導的氧化傷害及促進皮膚細胞增生和遷移之機制探討
|
蔡喻丞;Yu-Cheng Tsai |
| 國立臺灣大學 |
2016 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
Shao, Y-Y.; Chen, B-B.; Lin, Z-Z.; Hsu, C-H.; Wang, M-J.; Cheng, A-L.; Hsu, C.; 邵幼雲; 林宗哲; 鄭安理; 陳邦斌; 徐志宏; 許駿 |
| 臺大學術典藏 |
2020-04-10T12:16:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma (HCC): biomarker exploration
|
YU-YUN SHAO; Chen B.-B.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2022-08-19T00:20:40Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
CHIUN HSU; Wang M.-J.; Cheng A.-L.; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H. |
| 臺大學術典藏 |
2018-09-10T18:05:00Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y.-Y.;Chen, B.-B.;Ou, D.-L.;Lin, Z.-Z.;Hsu, C.-H.;Wang, M.-J.;Cheng, A.-L.;Hsu, C.; BANG-BIN CHEN; ANN-LII CHENG |
| 臺大學術典藏 |
2020-04-09T09:39:09Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao, Y. Y.; Chen, B. B.; Ou, D. L.; Lin, Z. Z.; Hsu, C. H.; Wang, M. J.; Cheng, A. L.; Hsu, C. |
| 臺大學術典藏 |
2020-04-10T12:15:58Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Yu-Yun Shao;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; YU-YUN SHAO; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-04-10T12:51:01Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Chiun Hsu; Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Chiun Hsu |
| 臺大學術典藏 |
2020-04-28T07:25:13Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Shao Y.-Y.;Chen B.-B.;Ou D.-L.;Lin Z.-Z.;Chih-Hung Hsu;Wang M.-J.;Cheng A.-L.;Hsu C.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; CHIH-HUNG HSU; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2020-07-03T08:45:42Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y;Chen B.-B;Da-Liang Ou;Lin Z.-Z;Hsu C.-H;Wang M.-J;Cheng A.-L;Hsu C.; Shao Y.-Y; Chen B.-B; DA-LIANG OU; Lin Z.-Z; Hsu C.-H; Wang M.-J; Cheng A.-L; Hsu C. |
| 臺大學術典藏 |
2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.;Bang-Bin Chen;Ou D.-L.;Lin Z.-Z.;Hsu C.-H.;Wang M.-J.;Cheng A.-L.;Hsu C.; Shao Y.-Y.; BANG-BIN CHEN; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-08-11T03:46:38Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 臺大學術典藏 |
2021-08-31T06:29:34Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; Lin Z.-Z.; Hsu C.-H.; Wang M.-J.; ANN-LII CHENG; Hsu C. |
| 臺大學術典藏 |
2022-06-10T06:10:59Z |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy
|
Shao Y.-Y.; Chen B.-B.; Ou D.-L.; ZHONG-ZHE LIN; Hsu C.-H.; Wang M.-J.; Cheng A.-L.; Hsu C. |
| 中山醫學大學 |
2020 |
Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
|
Tan, Tran-Der;Hong, Ying-Chung;Li, Sin-Syue;Yu, Jui-Ting;Sung, Yung-Chuan;Wang, Po-Nan;Teng, Chieh-Lin Jerry |
| 中山醫學大學 |
2020 |
Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
|
Tan, TD; Hong, YC; Li, SS; Yu, JT; Sung, YC; Wang, PN; Teng, CLJ |
| 國立成功大學 |
2020 |
Lenalidomide with dexamethasone to multiple myeloma patients relapsing from bortezomib-based induction therapies: A prospective, observational study
|
Tan, Tan T.-D.;Hong, Y.-C.;Li, S.-S.;Yu, J.-T.;Sung, Y.-C.;Wang, P.-N.;Teng, C.-L.J. |
